Institutional shares held 95.7 Million
95.4K calls
18.2K puts
Total value of holdings $426M
$424K calls
$80K puts
Market Cap $370M
80,634,800 Shares Out.
Institutional ownership 118.71%
# of Institutions 241


Latest Institutional Activity in MYGN

Top Purchases

Q2 2025
Assenagon Asset Management S.A. Shares Held: 325K ($1.49M)
Q2 2025
Janney Montgomery Scott LLC Shares Held: 164K ($751K)
Q2 2025
Public Employees Retirement System Of Ohio Shares Held: 59.1K ($271K)
Q2 2025
Wealth Enhancement Advisory Services, LLC Shares Held: 26.3K ($121K)
Q2 2025
Gsa Capital Partners LLP Shares Held: 11.2K ($51.5K)

Top Sells

Q2 2025
Fifth Third Bancorp Shares Held: 2.27K ($10.4K)
Q2 2025
Gamma Investing LLC Shares Held: 295 ($1.35K)
Q2 2025
Versant Capital Management, Inc Shares Held: 80 ($367)
Q2 2025
Massmutual Trust CO Fsb Shares Held: 123 ($565)
Q1 2025
Camber Capital Management LP Shares Held: 2.35M ($10.8M)

About MYGN

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, or metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, a RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, a RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. In addition, it provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, ADHD, and other mental health conditions. Myriad Genetics, Inc. has a strategic collaboration with Illumina, Inc. and Intermountain Precision Genomics for an offering of germline and somatic tumor testing services. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.


Insider Transactions at MYGN

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
1.72M Shares
From 19 Insiders
Grant, award, or other acquisition 1.72M shares
Sell / Disposition
519K Shares
From 15 Insiders
Payment of exercise price or tax liability 412K shares
Open market or private sale 107K shares

Track Institutional and Insider Activities on MYGN

Follow MYRIAD GENETICS INC and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells MYGN shares.

Notify only if

Insider Trading

Get notified when an Myriad Genetics Inc insider buys or sells MYGN shares.

Notify only if

News

Receive news related to MYRIAD GENETICS INC

Track Activities on MYGN